Athena Athena

X
[{"orgOrder":0,"company":"Petrovax","sponsor":"CanSino Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinese COVID-19 Vaccine Ad5-Ncov Shows High Antibody Levels at Russian Trial -Ifax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Petrovax","sponsor":"ISU ABXIS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ISU ABXIS has Signed a License Agreement for \u201cfabagal\u201d a Therapeutic for Fabry Disease, with NPO Petrovax Pharm Located in Russia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Petrovax","sponsor":"ISU ABXIS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fabagal\u00ae for Fabry Disease Management is Now Available in Russia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Petrovax

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Fabagal (agalsidase-beta) is a recombinant analogue of human alpha-galactosidase A and is produced by recombinant DNA technology. It is approved for the treatment of fabry disease in adults and children from 8 years old.

            Lead Product(s): Agalsidase Beta

            Therapeutic Area: Genetic Disease Product Name: Fabagal

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: ISU ABXIS

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 02, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Petrovax gains access to Fabagal (agalsidase beta), indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency).

            Lead Product(s): Agalsidase Beta

            Therapeutic Area: Genetic Disease Product Name: Fabagal

            Highest Development Status: Approved Product Type: Large molecule

            Recipient: ISU ABXIS

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 26, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies.

            Lead Product(s): Ad5-nCoV

            Therapeutic Area: Infections and Infectious Diseases Product Name: Convidecia

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: CanSino Biologics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 12, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY